Navigation Links
Cepheid Announces Preliminary 2008 Fourth Quarter and Full Year Revenue Results
Date:1/13/2009

SUNNYVALE, Calif., Jan. 13 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today announced preliminary revenue results for its 2008 fourth quarter and full year ended December 31, 2008.

Based on the company's preliminary financial results, total revenue for the fourth quarter of 2008 is expected to be approximately $38 million, with total product revenue of approximately $36 million. Total revenue for the full year ended December 31, 2008 is expected to be approximately $170 million, with total product revenue of approximately $159 million. Core clinical revenue is expected to be approximately $25 million for the fourth quarter of 2008, and approximately $91 million for the full year.

While detailed financial results are not yet available, the company expects to confirm 99 GeneXpert(R) system and 598 module placements in the fourth quarter. 45 of the GeneXpert placements and 426 modules were in North America. For the full year, GeneXpert system placements are expected to be 458 and module placements are expected to be 2,518.

Xpert(TM) MRSA test revenue is expected to be approximately $14 million for the fourth quarter of 2008, which compares to Xpert MRSA test revenue of approximately $5 million reported in the fourth quarter of 2007. For the full year, Xpert MRSA test revenue is expected to be approximately $47 million, which compares to 2007 revenue of approximately $9 million.

Fourth quarter and full year preliminary revenue results are pending finalization of the company's financial results for the quarter and year ended December 31, 2008 and accordingly are subject to change.

"While interest in our GeneXpert system and expanding menu of Xpert tests continues to grow, ongoing economic turbulence and uncertainty proved to have more of an impact on our customers th
'/>"/>

SOURCE Cepheid
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cepheid to Webcast Upcoming Financial Presentations
2. Cepheid Accelerates Direct Sales Channel in UK With Pending Acquisition of Medical Distributor Stretton Scientific
3. Cepheid Reports Third Quarter Revenue of $44.9 Million
4. Results of United Kingdom MRSA Surveillance Program Using Cepheid GeneXpert(R) System Demonstrate Benefits of Rapid Testing
5. Cepheid Molecular Diagnostic Test for MRSA and S. aureus Categorized Moderate Complexity by FDA
6. Cepheid Schedules Fiscal 2008 Third Quarter Financial Results Announcement and Webcast
7. Cepheid Receives FDA Clearance for First On-Demand Diagnostic Test for Life-Threatening MRSA and Staphylococcus aureus From Patient Positive Blood Cultures
8. Cepheid Receives FDA Clearance for First Rapid On-Demand Molecular Diagnostic Test for MRSA and S. aureus
9. Cepheid to Webcast Upcoming Financial Presentations
10. Cepheid Introduces GeneXpert(R) Infinity-48 System at 2008 American Association of Clinical Chemistry Meeting
11. Cepheid Reports Second Quarter Revenue of $42.1 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... Oct. 27, 2014 Janssen Biotech, Inc. ... (CCFA) announced today the launch of ... an educational campaign designed to provide resources for ... the paired role of nutrition and appropriate therapy ... multimedia assets associated with this release, please click: ...
(Date:10/26/2014)... The report "Data Center Networking Market ... WAN Optimization Appliances]: Global Advancements, Worldwide Forecasts & ... networking market into various segments with an in-depth ... identifies the factors driving this market, various restraints ... the future roadmaps. , Browse 106 market data ...
(Date:10/25/2014)... (PRWEB) October 25, 2014 The ... Type & by Geography - Global Trends & ... market with respect to market drivers, opportunities, and ... data tables and 27 figures spread through 217 ... - Global Trends & Forecast to 2019”., ...
(Date:10/25/2014)... October 23, 2014 BioProcess International ... for the 2014 BioProcess International Awards. The awards ... corporate responsibility and technology applications that will allow ... to a global patient base. , Winners and ... during a very entertaining and exciting awards dinner ...
Breaking Biology Technology:Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign 2Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign 3Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign 4Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 2Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 3Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 4Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 2Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 3Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 4BioProcess International Announces Winners of the 2014 BioProcess International Awards 2BioProcess International Announces Winners of the 2014 BioProcess International Awards 3BioProcess International Announces Winners of the 2014 BioProcess International Awards 4BioProcess International Announces Winners of the 2014 BioProcess International Awards 5
... EXTON, Pa., June 2, 2011 Morphotek®, Inc., a ... commenced a multi-center, phase II study of MORAb-004 for ... MORAb-004, a potentially first-in-class monoclonal antibody that specifically binds ... therapy comparing its safety and therapeutic activity at two ...
... a medical explanation for why exercise is good for the ... that started in Dr. Ian Phillips, lab at Keck Graduate ... 29 that keeps hearts healthy even under intense exercise. ... of why exercise is good for you," said Phillips, KGI,s ...
... (NASDAQ: SQNM ), a life sciences company ... its subsidiary Sequenom Center for Molecular Medicine® (Sequenom CMM) ... Valley Bank’s San Diego-based team. Sequenom will use proceeds ... of new products and other near term growth initiatives. ...
Cached Biology Technology:Morphotek®, Inc. Announces Initiation of MORAb-004 Phase II Study in Melanoma 2Morphotek®, Inc. Announces Initiation of MORAb-004 Phase II Study in Melanoma 3Scientists Discover Gene Regulator That Helps Hearts Through Exercise 2Sequenom Enters Into New $30.0 Million Credit Facility 2Sequenom Enters Into New $30.0 Million Credit Facility 3Sequenom Enters Into New $30.0 Million Credit Facility 4
(Date:10/29/2014)... number of chemicals from household and industrial products are ... bodies. But for most of them, scientists have yet ... taken the first step toward doing that by estimating ... new method is published in the ACS journal ... and colleagues note that the risks to human health ...
(Date:10/29/2014)... in German . ... and Peter Schlögelhofer at the Max F. Perutz Laboratories ... University of Vienna dived into the process of meiosis ... display an inversion of the standard meiotic phases. The ... Nature Communications . , Meiosis is the two-step ...
(Date:10/29/2014)... all organisms in the living world compete with ... strongly in how much they invest into their ... eager to get access to high-quality resources, while ... use of the lower-quality resources that are left ... in animal and human societies seems to fluctuate ...
Breaking Biology News(10 mins):Meiotic cell division 'the other way round' 2Evolution of competitiveness 2Evolution of competitiveness 3
... used in California,s Central Valley, one of the world,s ... frog species miles from farmland. Writing in Environmental ... Pacific Tree Fogs in remote mountain areas, including national ... pesticides by the elements. California,s Central Valley is ...
... 25, 2013 The following statement is being issued by Robbins Geller ... Pacific Biosciences Securities Litigation SUPERIOR COURT OF THE ... IN RE PACIFIC BIOSCIENCES OF CALIFORNIA ... CIV509210 SUMMARY NOTICE OF PROPOSED SETTLEMENT OF CLASS ACTION Hon. Marie ...
... researchers have developed a computer-aided method that uses ... rapid advances toward personalized health care, disease management ... V. Chawla and his doctoral student, Darcy A. ... Recommendation Engine (CARE) for personalized disease risk predictions ...
Cached Biology News:Pesticides contaminate frogs from Californian National Parks 2Robbins Geller Rudman & Dowd LLP and Scott+Scott, Attorneys at Law, LLP Announce Proposed Settlement of Class Action in the Pacific Biosciences Securities Litigation 2Robbins Geller Rudman & Dowd LLP and Scott+Scott, Attorneys at Law, LLP Announce Proposed Settlement of Class Action in the Pacific Biosciences Securities Litigation 3Robbins Geller Rudman & Dowd LLP and Scott+Scott, Attorneys at Law, LLP Announce Proposed Settlement of Class Action in the Pacific Biosciences Securities Litigation 4Notre Dame researchers develop system that uses a big data approach to personalized healthcare 2
This antibody detects an ~25 kDa band, corresponding to the expected molecular mass of Rab3A, on immunoblots. The antibody specificity is confirmed in peptide inhibition immunoblotting studies....
... reactive against the complex IV assembly factor SURF1. ... cultured cells. SURF1 is an important assembly factor ... participate in the folding of subunit II and ... SURF1, particularly ones that result in an absence ...
100 g monoclonal antibody which can immunocapture ~10 g of Complex IV from heart mitochondria. Also included are 2 mg of bovine heart mitochondria for control immunocapture....
Rabbit polyclonal to GPR56 ( Abpromise for all tested applications). entrezGeneID: 9289 SwissProtID: Q9Y653...
Biology Products: